Genscript Biotech (HK:1548) has released an update. Genscript Biotech’s associate, Legend Biotech, is making strides in the treatment of multiple myeloma, providing promising data from the Phase ...

Cell therapy biotech Tolerance Bio has unveiled with $17.2 million and a mission of targeting immune diseases by stretching and saving the function of a key organ. The Philadelphia biotech’s ...

SOMERSET, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Alan Bash as the ...

The projects have united Norwegian and Romanian expertise in biotechnology and health innovation to address the pressing need for affordable vaccines against the two diseases. For Romania ...

Commissions do not affect our editors' opinions or evaluations. Biotech stocks are not for the faint of heart. These highly volatile equities can see stomach-churning price swings, driven by how ...

In this interview, News Medical speaks with Dr Martin Biggs from Synoptics about Syngene's G:Box, a high-quality imaging and gel documentation system. In this interview, conducted at SfN 2024 in ...

During this process, the company hasn’t lost sight of the importance of drug R&D, Hughes explained during a recent interview with Fierce Biotech. While the interplay between developing copycat ...

Even during this tense election year, bipartisan coalitions are taking steps to enhance national security, protect American-owned intellectual property and secure the country’s supply chain by ...

The field of Biodesign holds immense potential in transforming our understanding of the brain and enhancing the capabilities of biotech devices. Over the past decade, this interdisciplinary area has ...

Since it was founded nearly two decades ago, 23andMe has grown into one of the largest biotechnology companies in the world. Millions of people have used its simple genetic testing service ...

However, the biotech has what it takes to be successful in the challenging gene-editing niche. This company might be worth far more than many realize. If I had to buy one share of any biotech with ...